News
We are introducing two new screening tests for colon and lung cancer.
03. 12. 2025
GHC Genetics has introduced two new non-invasive screening tests, PulmoScreen and ColonScreen, which can detect serious diseases before they manifest themselves. These are blood screening tests for lung cancer and colorectal cancer. Both tests are based on the so-called analysis of DNA methylation in a blood sample and represent a modern, fast, and highly accessible form of prevention that can detect very early pathological changes in cells that later lead to the development of cancerous growths. By introducing these two screening tests, we are strengthening our position in the field of personalized and predictive medicine. We are putting into practice methods that were only available in research a few years ago. Thanks to them, we can help detect the disease at a stage when treatment is most effective, and patients have the best chance of a full recovery.
GHC Genetics to use innovative approach in sequencing oral and intestinal microbiome
11. 11. 2025
Nanopore sequencing belongs to the so-called "third generation" of sequencing, which allows direct reading of single-stranded DNA or RNA without the need for prior amplification (e.g., using PCR) or chemical labeling. The use of nanopores for sequencing was first described in the late 1980s by several American scientists. David Deamer, George Church, and Hagan Bayley independently described the sequencing of a single DNA molecule using electrophoresis and membrane nanopores. This method does not use a fluorescent signal, but measures the voltage changes that occur when DNA passes through an electrically charged pore in the membrane.
More infoWe are vaccinating against COVID-19 again (Comirnaty vaccine LP.8.1.)
22. 09. 2025
At the GHC Genetics clinic, we will once again be administering COVID-19 vaccinations starting October 1, 2025.
More info
